OncoCyte Corporation
US ˙ NasdaqCM ˙ US68235C2061
DETTE SYMBOL ER IKKE LÆNGERE AKTIVT

SecurityOCX / OncoCyte Corporation
InstitutionState Street Corp
Latest Disclosed Ownership50,754 shares
Latest Disclosed Value $ 166,473
State Street Corp reports 6.28% increase in ownership of OCX / OncoCyte Corporation

On May 15, 2026 - State Street Corp filed a 13F-HR form disclosing ownership of 50,754 shares of OncoCyte Corporation (US:OCX) valued at $166,473 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 47,754 shares of OncoCyte Corporation. This represents a change in shares of 6.28% during the quarter. The current value of the position is $162,413 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 50,754 3,000 6.28 166 -53.63 0.0000
2026-02-13 2025-12-31 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 47,754 5,900 14.10 358 159.42 0.0000
2025-11-14 2025-09-30 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 41,854 22,300 114.04 139 133.90 0.0000
2025-08-14 2025-06-30 13F INSIGHT MOLECULAR DIA COM NEW 68235C206 19,554 0 0.00 59 0.00 0.0000
2025-05-15 2025-03-31 13F ONCOCYTE COM NEW 68235C206 19,554 0 0.00 60 28.26 0.0000
2025-02-14 2024-12-31 13F ONCOCYTE COM NEW 68235C206 19,554 0 0.00 47 -16.36 0.0000
2024-11-14 2024-09-30 13F ONCOCYTE COM NEW 68235C206 19,554 0 0.00 56 -3.51 0.0000
2024-08-14 2024-06-30 13F ONCOCYTE COM NEW 68235C206 19,554 3,265 20.04 58 21.28 0.0000
2024-05-15 2024-03-31 13F ONCOCYTE COM NEW 68235C206 16,289 0 0.00 48 17.50 0.0000
2024-02-14 2023-12-31 13F ONCOCYTE COM NEW 68235C206 16,289 0 0.00 40 -24.53 0.0000
2023-11-14 2023-09-30 13F ONCOCYTE COM NEW 68235C206 16,289 16,289 53 0.0000
2023-08-14 2023-06-30 13F ONCOCYTE COM 68235C107 281,845 0 0.00 65 -35.35 0.0000
2023-05-15 2023-03-31 13F ONCOCYTE COM 68235C107 281,845 0 0.00 100 10.00 0.0000
2023-05-15 2022-12-31 13F/A-99 ONCOCYTE COM 68235C107 281,845 0 0.00 90 -56.31 0.0000
2023-05-15 2022-12-31 13F ONCOCYTE COM 68235C107 281,845 0 90 0.0000
2022-11-15 2022-09-30 13F ONCOCYTE COM 68235C107 281,845 -45,300 -13.85 206 -29.93 0.0000
2022-08-15 2022-06-30 13F ONCOCYTE COM 68235C107 327,145 -1,030,368 -75.90 294 -85.47 0.0000
2022-05-16 2022-03-31 13F ONCOCYTE COM 68235C107 1,357,513 -27,948 -2.02 2,023 -32.70 0.0001
2022-02-14 2021-12-31 13F ONCOCYTE COM 68235C107 1,385,461 -18,103 -1.29 3,006 -39.84 0.0001
2021-11-15 2021-09-30 13F ONCOCYTE COM 68235C107 1,403,564 140,365 11.11 4,997 -31.09 0.0003
2021-08-16 2021-06-30 13F ONCOCYTE COM 68235C107 1,263,199 153,843 13.87 7,251 25.93 0.0004
2021-07-09 2021-03-31 13F/A-1 ONCOCYTE COM 68235C107 1,109,356 176,876 18.97 5,758 158.32 0.0003
2021-05-17 2021-03-31 13F ONCOCYTE COM 68235C107 1,109,356 176,876 5,758 0.0003
2021-02-16 2020-12-31 13F ONCOCYTE COM 68235C107 932,480 247,843 36.20 2,229 134.14 0.0001
2020-11-10 2020-09-30 13F ONCOCYTE COM 68235C107 684,637 59,985 9.60 952 -20.20 0.0001
2020-08-14 2020-06-30 13F ONCOCYTE COM 68235C107 624,652 195,794 45.65 1,193 13.51 0.0001
2020-06-19 2020-03-31 13F/A-1 ONCOCYTE COM 68235C107 428,858 -6,350 -1.46 1,051 7.35 0.0001
2020-05-11 2020-03-31 13F ONCOCYTE COM 68235C107 428,858 -6,350 1,051 92.2990
2020-02-06 2019-12-31 13F ONCOCYTE COM 68235C107 435,208 14,375 3.42 979 10.75 0.0001
2019-11-14 2019-09-30 13F ONCOCYTE COM 68235C107 420,833 68,513 19.45 884 0.80 0.0001
2019-08-14 2019-06-30 13F ONCOCYTE COM 68235C107 352,320 352,320 877 0.0001
2018-08-14 2018-06-30 13F ONCOCYTE Common equity shares 68235C107 0 -18,211 -100.00 0 -100.00
2018-05-15 2018-03-31 13F ONCOCYTE Common equity shares 68235C107 18,211 2,312 14.54 39 -46.58 0.0000
2018-02-14 2017-12-31 13F ONCOCYTE Common equity shares 68235C107 15,899 -20,227 -55.99 73 -55.21 0.0000
2016-05-20 2016-03-31 13F/A-1 ONCOCYTE Common equity shares 68235C107 36,126 36,126 163 0.0000
2016-05-12 2016-03-31 13F ONCOCYTE Common equity shares 68235C107 36,126 163
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.